BR112018072755A2 - composto de fórmula geral, processo para a preparação, composto para uso e composição farmacêutica - Google Patents

composto de fórmula geral, processo para a preparação, composto para uso e composição farmacêutica

Info

Publication number
BR112018072755A2
BR112018072755A2 BR112018072755-5A BR112018072755A BR112018072755A2 BR 112018072755 A2 BR112018072755 A2 BR 112018072755A2 BR 112018072755 A BR112018072755 A BR 112018072755A BR 112018072755 A2 BR112018072755 A2 BR 112018072755A2
Authority
BR
Brazil
Prior art keywords
compound
formula
preparation
subunit
voltage
Prior art date
Application number
BR112018072755-5A
Other languages
English (en)
Inventor
Cuevas-Cordobés Félix
Almansa-Rosales Carmen
Original Assignee
Esteve Pharmaceuticals, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals, S.A. filed Critical Esteve Pharmaceuticals, S.A.
Publication of BR112018072755A2 publication Critical patent/BR112018072755A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

a presente invenção se refere a compostos inovadores de fórmula geral (i) que mostram uma grande afinidade e atividade com relação à subunidade a2d dos canais de cálcio dependentes de voltagem (vgcc), especialmente a subunidade a2d-1 dos canais de cálcio dependentes de voltagem, ou uma atividade dual com relação à subunidade a2d dos canais de cálcio dependentes de voltagem (vgcc), especialmente a subunidade a2d-1 dos canais de cálcio dependentes de voltagem, e o transportador de noradrenalina (net). a invenção também se refere ao processo para a preparação dos ditos compostos, assim como também às composições que compreendem os mesmos e o seu uso como medicamentos.
BR112018072755-5A 2016-05-06 2017-05-05 composto de fórmula geral, processo para a preparação, composto para uso e composição farmacêutica BR112018072755A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382199 2016-05-06
EP16382199.4 2016-05-06
PCT/EP2017/060780 WO2017191304A1 (en) 2016-05-06 2017-05-05 Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions

Publications (1)

Publication Number Publication Date
BR112018072755A2 true BR112018072755A2 (pt) 2019-02-19

Family

ID=56024209

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072755-5A BR112018072755A2 (pt) 2016-05-06 2017-05-05 composto de fórmula geral, processo para a preparação, composto para uso e composição farmacêutica

Country Status (32)

Country Link
US (1) US10590140B2 (pt)
EP (1) EP3452475B1 (pt)
JP (1) JP6926197B2 (pt)
KR (1) KR20190024876A (pt)
CN (1) CN109526220B (pt)
AR (1) AR108387A1 (pt)
AU (1) AU2017260305B2 (pt)
BR (1) BR112018072755A2 (pt)
CA (1) CA3023379A1 (pt)
CO (1) CO2018012002A2 (pt)
CY (1) CY1123231T1 (pt)
DK (1) DK3452475T3 (pt)
ES (1) ES2789676T3 (pt)
HR (1) HRP20200668T1 (pt)
HU (1) HUE051829T2 (pt)
IL (1) IL262825A (pt)
LT (1) LT3452475T (pt)
ME (1) ME03726B (pt)
MX (1) MX2018013471A (pt)
MY (1) MY196791A (pt)
PH (1) PH12018502337A1 (pt)
PL (1) PL3452475T3 (pt)
PT (1) PT3452475T (pt)
RS (1) RS60528B1 (pt)
RU (1) RU2018141084A (pt)
SG (1) SG11201809799WA (pt)
SI (1) SI3452475T1 (pt)
TN (1) TN2018000372A1 (pt)
TW (1) TWI736619B (pt)
UA (1) UA123789C2 (pt)
WO (1) WO2017191304A1 (pt)
ZA (1) ZA201807653B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3697754A1 (en) 2017-10-16 2020-08-26 Esteve Pharmaceuticals, S.A. Propanamine derivatives for treating pain and pain related conditions
CA3084425A1 (en) * 2017-10-27 2019-05-02 Esteve Pharmaceuticals, S.A. New alcoxyamino derivatives for treating pain and pain related conditions
WO2019110137A1 (en) * 2017-12-04 2019-06-13 Esteve Pharmaceuticals, S.A. O-phenoxy and o-benzyloxypropylamino derivatives having activity against pain
WO2019115008A1 (en) * 2017-12-12 2019-06-20 Esteve Pharmaceuticals, S.A. Dialkylaminoarylpiperidinyl-o-phenoxy and o-benzyloxypropylamino derivatives having multimodal activity against pain
WO2019149919A1 (en) * 2018-02-05 2019-08-08 Esteve Pharmaceuticals, S.A. Aminopropoxypiperidinylamido derivatives having multimodal activity against pain
WO2020089263A1 (en) * 2018-10-31 2020-05-07 Esteve Pharmaceuticals, S.A. Optionally nitrogenated isoquinolin-1(2h)-ones and 1h-isochromen- 1-ones for treating pain and pain related conditions
CN113166147A (zh) * 2018-11-02 2021-07-23 埃斯特韦制药股份公司 用于治疗疼痛和疼痛相关病症的新的四氢嘧啶二氮杂卓和四氢吡啶二氮杂卓化合物
AR116972A1 (es) * 2018-11-02 2021-06-30 Esteve Pharmaceuticals Sa Derivados de alcoxiaminopiridina para tratar dolor y estados relacionados con dolor
JPWO2020175680A1 (pt) * 2019-02-28 2020-09-03

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0303074A3 (en) * 2000-09-27 2007-08-28 Ajinomoto Kk Benzodiazepine derivatives and pharmaceutical compositions them
PL375090A1 (en) 2002-06-27 2005-11-14 Warner-Lambert Company Llc Method of treating attention deficit hyperactivity disorder
WO2005085210A1 (ja) * 2004-03-10 2005-09-15 Ono Pharmaceutical Co., Ltd. ニトリル化合物およびその化合物を有効成分として含有する医薬組成物
CN101420955B (zh) * 2006-02-14 2013-07-17 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的二氢二氮杂*
TW200914457A (en) 2007-05-31 2009-04-01 Kyowa Hakko Kogyo Kk Pyrimidodiazepinone derivative
UY32622A (es) * 2009-05-12 2010-12-31 Astrazeneca Ab Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)

Also Published As

Publication number Publication date
EP3452475B1 (en) 2020-02-26
PH12018502337A1 (en) 2019-07-08
ME03726B (me) 2021-01-20
JP6926197B2 (ja) 2021-08-25
HUE051829T2 (hu) 2021-03-29
KR20190024876A (ko) 2019-03-08
CO2018012002A2 (es) 2019-04-30
EP3452475A1 (en) 2019-03-13
RU2018141084A (ru) 2020-06-08
JP2019515039A (ja) 2019-06-06
TN2018000372A1 (en) 2020-06-15
UA123789C2 (uk) 2021-06-02
AR108387A1 (es) 2018-08-15
AU2017260305B2 (en) 2021-04-01
TW201808955A (zh) 2018-03-16
LT3452475T (lt) 2020-05-11
ES2789676T3 (es) 2020-10-26
ZA201807653B (en) 2019-06-26
SI3452475T1 (sl) 2020-07-31
CA3023379A1 (en) 2017-11-09
AU2017260305A1 (en) 2018-12-13
TWI736619B (zh) 2021-08-21
CY1123231T1 (el) 2021-10-29
CN109526220A (zh) 2019-03-26
PT3452475T (pt) 2020-05-05
IL262825A (en) 2018-12-31
MX2018013471A (es) 2019-06-06
RS60528B1 (sr) 2020-08-31
CN109526220B (zh) 2021-12-21
HRP20200668T1 (hr) 2020-10-16
MY196791A (en) 2023-05-03
DK3452475T3 (da) 2020-04-27
SG11201809799WA (en) 2018-12-28
US10590140B2 (en) 2020-03-17
US20190144455A1 (en) 2019-05-16
WO2017191304A1 (en) 2017-11-09
PL3452475T3 (pl) 2020-08-24
RU2018141084A3 (pt) 2020-06-11

Similar Documents

Publication Publication Date Title
BR112018072755A2 (pt) composto de fórmula geral, processo para a preparação, composto para uso e composição farmacêutica
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
CY1120673T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112018006448A2 (pt) derivado de oxaespiro, método de preparação dos mesmos, e aplicações dos mesmos em medicamentos
BR112018007381A2 (pt) compostos úteis como imunomoduladores
BR112018003595A2 (pt) análogos de nucleosídeos substituídos no anel aromático 6-6 bicíclico para uso como inibidores de prmt5
DOP2015000245A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
BR112017012327A8 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
BR112016028476A8 (pt) compostos, composição, uso de um composto e método para o combate dos fungos nocivos
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112016005270A2 (pt) compostos de aza-piridona, composições farmacêuticas e seus usos
BR112017023764A2 (pt) derivados de ciclohexano substituído por amido
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
BR112017023740A2 (pt) ?forma sólida de um composto, processo para a preparação de uma forma sólida, composição farmacêutica, método para o tratamento ou prevenção de doenças e utilização de uma forma sólida?
BR112018072545A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112018011969A2 (pt) compostos heteroaromáticos como inibidores de btk
BR112017004741A2 (pt) compostos e composições como inibidores da raf quinase
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112017004173A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica.
BR112017011980A2 (pt) composto, composição farmacêutica, e, método para tratar uma infecção bacteriana.
BR112017012005A2 (pt) compostos orgânicos
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2721 DE 28-02-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.